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Abstract 
 
 
On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel 
(KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric 
antigen receptor - T cells (CAR-T), for the treatment of children and young adults with 
relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized 
cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T 
program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To 
address these issues, experts representing the American Society for Blood and Marrow Transplant 
(ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International 
Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular 
Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent 
for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in 
patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice 
scenarios that will become more prevalent now that the first commercially available CAR-T product 
for B-ALL has been approved. 
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Introduction:  
Chimeric Antigen Receptors (CAR) are engineered fusion proteins that combine an extracellular 
antigen-binding domain with one or more intracellular T-cell signaling domains. CAR-T cells (CAR-
T) use gene transfer technology (such as lentiviral or retroviral vectors) to reprogram patients’ T cells 
to express CARs thereby re-directing their specificity, through a mechanism independent of Major 
Histocompatibility Complex, to target specific tumor antigens1. In August 2017, the United States 
Food and Drug Administration (US-FDA) had a landmark approval of the drug tisagenlecleucel 
(KYMRIAH; Novartis, Basel, Switzerland) for the treatment of patients up to 25 years of age with 
relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). In June 2018, the Committee for 
Human Medicinal Products (CHMP) at the European Medicines Agency (EMA) recommended 
approval of tisagenlecleucel for the same indication. While the science underlying CAR-T heralds a 
new therapeutic era, the treatment has risk of serious adverse effects. There are many challenges 
facing its utilization outside clinical trials such as determining eligibility of patients to receive this 
treatment and the significant financial burden on the healthcare system. Moreover, many more 
questions have arisen regarding the future impact of CAR-T therapy on the use of allogeneic 
hematopoietic cell transplantation (allo-HCT), since many patients with B-ALL undergo HCT.  
 
Commissioned by the American Society for Blood and Marrow Transplant (ASBMT) Practice 
Guidelines Committee and the Acute Leukemia Working Party of the European Group for Blood and 
Marrow Transplantation (EBMT), a global CAR-T Task Force was developed to help identify and 
address the key challenges in the treatment and management of patients with relapsed or refractory B-
ALL destined to undergo treatment with anti CD19 CAR-T such as tisagenlecleucel. The Task Force 
included representatives from ASBMT, EBMT, the International Society of Cell and Gene Therapy 
(ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT). The Task Force 
committee met twice (2017 and 2018) and identified 10 key clinical practice questions and/or clinical 
scenarios relevant to clinical hematologists and allied health practitioners regarding the use of CAR-T 
in B-ALL. Practice guidelines from this initiative for each particular question forms the basis of this 
article and lays out a roadmap of common issues encountered with planning and delivering CAR-T 
therapy for B-ALL with reference to both the commercially available products and on clinical trials.  
 
1. Where and when should patients be referred for CAR-T in B-cell acute lymphoblastic 
leukemia?  
Tisagenlecleucel (KYMRIAH
TM
) is the first CAR-T therapy approved for treatment of children and 
young adults with refractory or in second or later relapse of B-ALL
2
. For safe delivery of CAR-T 
therapy, a robust clinical infrastructure is required to handle the complex scheduling logistics, 
maintain the chain-of-custody and chain-of-identity of the cellular product, and facilitate 
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communication to manage potentially severe toxicities. Several organizations are involved in 
standardization and regulation of this process. The FDA oversees approval and regulation of the 
products, manages adverse event reporting, and supervises Risk Evaluation and Mitigation Strategy 
(REMS) process in partnership with the manufacturers. FACT provides standards for handling, 
processing, and tracking of immune effector cells, and in collaboration with The Joint Accreditation 
Committee ISCT-Europe & EBMT (JACIE), provides oversight of the blood and marrow transplant 
unit around the globe. The Center for International Blood and Marrow Transplant Research 
(CIBMTR) and EBMT functions as a data repository and a conduit between centers and the 
regulatory authorities for transplant outcomes reporting. Finally, manufacturers themselves inspect 
apheresis and storage facilities, and authorize individual centers to provide therapeutics. To  fulfil 
these robust requirements for a safe delivery of CAR-T, currently only selected larger institutions are 
selected for performing CAR-T therapy, and these are typically centers with allo-HCT experience as 
they are already performing similar process for HCT.
3
  
In Figure 1, we suggest various indications for referral to centers offering CAR-T for treatment of 
relapsed/refractory B-ALL. In brief, tisagenlecleucel is FDA approved for patients 25 years and 
younger with B-ALL who have experienced a second or greater bone marrow or extra medullary 
relapse or have refractory disease after initial diagnosis or after treatment for first relapse. In addition, 
we suggest referring patients with induction failure, early relapse after achieving first complete 
remission, and adult patients with relapsed/refractory B-ALL to CAR-T cell therapy programs to 
allow discussion of the optimal timing of apheresis and potential of enrollment in CAR-T clinical 
trials.   
It is important to note that most patients treated on clinical trials of anti CD19 CAR-T therapy to date 
have had active disease at the time of enrollment and that this therapy is effective in patients who are 
not in remission, which is distinct from allo-HCT for B-ALL.  Thus, we recommend prompt referral 
to a CAR-T center as soon as a patient meets referral criteria (e.g. at the time of relapse, before 
starting therapy if possible,) especially as specified recovery periods from prior therapy are required 
before leukapheresis (Figure 2).  This is particularly important as evidence suggests that the quality 
of circulating T-cells decreases with increasing prior chemotherapy exposure.
4
  Patients without high 
peripheral disease burden and sufficient circulating T-cells (and absolute lymphocyte count of >500 
cells/uL or a peripheral blood CD3 count of >150 cells/uL) may be able to undergo leukapheresis for 
tisagenlecleucel before starting therapy for relapse.  For other patients, bridging therapy should be 
planned in conjunction with the CAR-T therapy center to avoid therapies (in particular clofarabine) 
which are likely to significantly impair lymphocyte number and/or function in order to allow 
successful leukapheresis for CAR-T cell therapy. 
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2. Is the sequence of CAR-T therapy with blinatumomab and/or inotuzumab important?  
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of 
relapsed or refractory B-ALL in adults and children. As tisagenlecleucel targets CD19, there are 
theoretical concerns that blinatumomab pretreatment will make patients ineligible for tisagenlecleucel 
therapy by potentially selecting for CD19 negative populations
5
. While the global ELIANA trial 
excluded patients with prior blinatumomab exposure, multiple phase I and phase II trials have 
described the feasibility, safety and even efficacy of anti-CD19 CAR-T therapy after blinatumomab 
use
6-8
. In a Phase I study from the University of Pennsylvania
6
 using anti-CD19 CAR-T (CD19 CAR-
T) in children and young adults, 4 of 5 patients who were previously refractory to blinatumomab 
achieved complete remission (CR) with a 41BB CD19 CAR-T but 3 patients subsequently relapsed 
with CD19 negative disease. Also, a single center study from Memorial Sloan Kettering Cancer 
Center (MSKCC) reported infusion of CD28z CD19 CAR-T in 13 (25%) patients previously treated 
with blinatumomab, and 9 of the 13 achieved CR after receipt of CAR-T
7
. Although CD19 CAR-T 
and blinatumomab target the same antigen, blinatumomab activity is constrained by the number and 
function of endogenous T cells, in contrast to CAR-T, which constitutively express a CD19-specific 
receptor and undergo prompt and robust in vivo expansion. It has also been reported that 
blinatumomab activity is partially restricted to regulatory T-cell (Treg) numbers, and those with high 
Tregs in peripheral blood show increased risk of failure to respond to blinatumomab. 
Lymphodepleting therapy with cyclophosphamide and fludarabine, may reduce Treg numbers.
9
 
Hence, prior use of blinatumomab (irrespective of the response) in our opinion is not considered an 
absolute contraindication for the use of tisagenlecleucel, however the CD19 status of the 
relapsed/refractory B-ALL (flow cytometry on bone marrow sample) should be considered in the 
decision to prescribe tisagenlecleucel, as the impact on remission durability amongst those with pre-
treatment blinatumomab is not firmly established.  
 
Inotuzumab ozogamicin (IO) is an anti-CD22-calicheamicin conjugate approved for the treatment of 
adults with relapsed or refractory B-ALL
10
. Since tisagenlecleucel targets CD19, prior IO use should 
not diminish the efficacy of anti CD19 CAR-T therapy, hence previous use of IO should not be 
considered an exclusion for anti CD19 CAR-T therapy. However, it is important to note that IO 
induces a period of B-cell aplasia following treatment by targeting CD22 on both normal and 
malignant B-cells.  The effect that this may have on the expansion and persistence of CAR-T by 
reducing the number of CD19 positive cells that stimulate the growth of tisagenlecleucel is unknown.  
Studies of another anti CD19 CAR-T for the treatment of pediatric leukemia have shown that patients 
with fewer than 15% CD19 positive cells in the bone marrow at the time of infusion had shorter 
persistence of functional CAR-T as measured by the duration of B-cell aplasia.
11
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3. What is the optimal strategy to manage bridging chemotherapy and administer 
lymphodepleting chemotherapy between T-cell collection and infusion of CAR-T?  
 
Bridging chemotherapy: 
Given the current clinically approved indications for anti CD19 CAR-T, patients referred for CAR-T 
therapy are often in active relapse or have refractory disease. Therefore, chemotherapy after T-cell 
collection by leukapheresis is usually required to control disease until the manufacturing of CAR-T is 
complete. Bridging chemotherapy should focus on disease control rather than remission induction 
while minimizing organ toxicity or risk of infections.  Of 92 patients enrolled on the ELIANA trial, 
10 patients had significant adverse events or death between T-cell harvest and CAR-T infusion 
preventing the receipt of tisagenlecleucel.  Among 75 patients who received a CAR-T infusion, 65 
(87%) were treated with bridging chemotherapy between enrollment and infusion
2
.  Table 1 describes 
various chemotherapy considerations for bridging therapy and how to manage them in relation to 
CAR-T infusion. The choice of bridging therapy depends on a patient’s previous treatment history 
and should be timed and coordinated closely with the CAR-T manufacturing / treating institution to 
avoid delays in the infusion of CAR-T therapy. As mentioned above, previous use of blinatumomab is 
not an absolute contraindication for receiving anti CD19 CAR-T therapy, however to minimize the 
risk of antigen loss and until more robust data are available, this therapy should ideally be avoided as 
a bridging chemotherapy.  
Lymphodepleting chemotherapy prior to infusion of CAR-T: 
Preclinical studies have shown that lymphodepleting chemotherapy immediately before CAR-T 
infusion reduces tumor burden while enhancing CAR-T expansion and persistence, likely by 
depletion of conventional and Tregs, and increasing cytokines driving homeostatic expansion. If there 
is a potential for an anti-CAR-T immune response, this may be reduced as well
12
. The ELIANA trial 
used a moderate dose regimen of fludarabine (30mg/m2 intravenously daily for 4 days) and 
cyclophosphamide (500 mg/m2 intravenously daily for 2 days starting with the first dose of 
fludarabine) followed by infusion of CAR-T, 2 to 14 days after completion of lymphodepleting 
chemotherapy. While not studied in a randomized fashion, clinical data has generally supported the 
importance of lymphodepleting chemotherapy as well.  In the ELIANA trial, three patients did not 
receive lymphodepleting chemotherapy due to leukopenia but their outcomes were not separately 
reported. In another clinical trial of 30 patients with relapsed/refractory B-ALL conducted at the Fred 
Hutchinson Cancer Research Center (FHCRC), 17 patients who received fludarabine and 
cyclophosphamide based lymphodepletion had improved persistence of CAR-T  and better disease 
free survival compared to 13 patients who received either cyclophosphamide alone or 
cyclophosphamide with etoposide based lymphodepletion
13
. Similarly, a clinical trial of 53 patients 
conduced at the NCI for pediatric and young adults with relapsed/refractory ALL used different 
lymphodepleting chemotherapy regimen over the course of the clinical trial and based it on the 
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disease burden at time of enrollment. There was no benefit to adjusting the lymphodepleting 
chemotherapy regimen based on disease burden, but overall survival in subjects receiving a 
fludarabine/cyclophosphamide regimen was significantly longer compared to those who received an 
alternative regimen.
14
  
Conversely, a handful of patients have received CAR-T therapy on clinical trials without antecedent 
lymphodepletion, including the first pediatric ALL patient successfully treated with CD19 CAR-T.
15
 
In the NCI adult CAR-T trial, 4 of 5 patients with B-ALL treated with donor-derived CAR-T therapy 
without antecedent lymphodepletion achieved measurable residual disease negative (MRD-negative) 
CR
15
.  
Currently, we recommend that patients receive fludarabine/cyclophosphamide lymphodepleting 
chemotherapy prior to tisagenlecleucel infusion as detailed in the package insert of the approved 
product and adherence to timing between lymphodepleting chemotherapy and CAR-T infusion is 
important. It may be appropriate for some patients with low lymphocyte counts and/or pancytopenia 
from disease or prior therapy to forgo lymphodepleting chemotherapy on a risk-benefit basis, with 
knowledge that outcomes data for this subgroup of patients is limited. Myeloid growth factors, 
particularly granulocyte-macrophage colony-stimulating factor (GM-CSF), are not recommended 
during the first 3 weeks after KYMRIAH infusion or until CRS has resolved.  
 
4. Are CAR-T a bridging therapy to allo-HCT or sufficient alone as definitive relapse therapy?  
For a patient who has never undergone allo-HCT and enters a CR after anti-CD19 CAR-T, a critical 
question is whether to consolidate the CR with allo-HCT. CAR-T therapy, while effective, and 
durable in subgroup of patients, does not prevent antigen negative escape.  
The NCI conducted a Phase I trial for children and young adults with relapsed/refractory CD19 
positive or CD22 positive ALL to be treated with anti CD19 or anti-CD-22 CAR-T protocols 
respectively. 52 patients were enrolled on anti CD19 and 33 patients on anti-CD22 CAR-T trial.
16
 The 
anti-CD19 CAR-T construct utilized a CD28 costimulatory domain; while the anti-CD22 CAR-T 
incorporated 41BB. In the most recent updates presented at 2018 BMT Tandem Meetings, 51 patients 
attained a CR, of whom 43 were MRD-negative by flow cytometry and 25 subsequently underwent 
allo-HCT. In a competing risks analysis of relapse versus transplant related mortality, and limited to 
first allo-HCT after CAR-T, it was shown that the 24-month cumulative incidence of post allo-HCT 
relapse was 13.5% (95% CI: 3.2-32.1%) after anti CD19 CAR-T and 11.3% (95% CI: 1.7-31.1%) 
after CD22 CAR-T. These two non-randomized trials suggest the potential synergistic role of CAR-T 
therapy with allo-HCT to improve leukemia free survival, prior to emergence of antigen negative 
leukemia, without an increased risk of severe graft-versus-host disease (GVHD). 
16
 
In contrast, among 17 of 53 adults who underwent allo-HCT at MSKCC after anti CD19 CAR-T with 
a CD28 co-stimulatory domain, five were alive in CR, six relapsed, and six died from transplant-
related mortality. On further evaluation of the 32 patients with MRD-negative CR, there was no 
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significant difference in overall survival (OS) between patients who underwent allo-HCT and those 
who did not (P=0.89)
7
.  
To further elucidate the importance of disease burden pre-CAR-T therapy, patients were divided in 
low disease burden (<5% bone marrow blasts) and high disease burden ( 5% bone marrow blasts or 
extra-medullary disease). Patients with low disease burden at time of T-cell infusion had significantly 
longer event-free survival and OS than those with a high disease burden. The median OS among 
patients with a low disease burden was 20.1 months (95% CI, 8.7 to not reached), as compared with 
12.4 months (95% CI, 5.9 to 20.7) among those with a high disease burden (P = 0.02). The significant 
difference in OS according to disease burden remained unaffected even when allo-HSCT after CAR-T 
therapy was included in the analysis. Because of the non-randomized nature of the trial, it is 
impossible to determine whether patients who were considered at greater risk of relapse were among 
those treated with allo-HCT as consolidation.  
In the ELIANA trial which infused 75 patients using the anti CD19 CAR-T (with a 41BB 
costimulatory domain), only eight patients (9%) underwent allo-HCT while in remission, including 
two patients with MRD-positive bone marrow, and two with B-cell recovery within 6 months after 
infusion. All eight patients who underwent allo-HCT were alive at last follow up, 4 with no relapse, 
and 4 with no unknown disease status. This cohort, therefore, is largely representative of outcomes 
after tisagenlecleucel without subsequent therapy, which notably includes only a population that is 
blinatumomab naïve. In the most recent update presented at American Society of Hematology 2018, 
the relapse-free rate was 80% at 6 months and 66% at 12 and 18 months.
17
 Overall survival was 
nearly identical whether patients were censored at the time of SCT or not. The durability of the 
clinical response was associated with persistence of tisagenlecleucel in peripheral blood and persistent 
B-cell aplasia which is the biological correlate of ongoing CAR-T cell activity.  
In the absence of long-term follow-up and given the small number of patients in the above studies 
with many differences including the CAR-T construct, co-stimulatory domain, conditioning therapy 
and previous allo-HCT, we must consider that this is an open question. In patients who have not had a 
prior allo-HCT, this follow on therapy must at least be considered. On the other hand, in patients who 
have relapsed after prior allo-HCT, the utility of second allo-HCT is also quite unclear. At this point, 
with studies still underway to determine who might benefit from post-CAR-T consolidation with an 
allo-HCT, we suggest evaluating individual patient factors (quality of available donor, comorbidities), 
disease related factors (MRD status, and B cell aplasia), and CAR-T related factors (co-stimulatory 
domain and potential persistence of CAR-T) when considering allo-HCT following anti CD19 CAR-T 
therapy for a patient who is allo-HCT naïve.   
 
5. What are the key considerations in using CAR-T after allo-HCT? 
Prior to the availability of CAR-T therapy, there is no standard approach for treatment of a patient 
with relapsed/refractory B-ALL after allo-HCT and outcomes remain dismal in this setting. Donor 
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lymphocyte infusion (DLI) and withdrawal of immune suppression result in < 10% CR rates and most 
remissions are transient
18
. Adoptive transfer of autologous anti CD19 CAR-T has demonstrated the 
potency of this therapy in patients with relapsed/refractory B-ALL with a potential for long-term 
disease control.  61% of patients enrolled to ELIANA study had relapsed/refractory disease after allo-
HCT. Generally, T-cells were successfully collected from post-HCT recipients and most were most 
likely of donor origin. High remission rates were seen in these studies and GVHD was not a 
significant treatment-related toxicity
2, 7, 8
. To clarify terminology, even though these T-cells were 
derived from an allogeneic graft, the cells are “autologous” because they are collected from the 
patient who will receive the CAR-T therapy.   
There has been only one case each of acute and chronic GVHD reported in autologous CAR-T cell 
trials, both in the setting of trials using defined compositions of T cells. In a study from FHCRC
13
, 
CAR-T products defined by a 1:1 ratio of CD4:CD8 cells were administered to 27 adult patients, 11 
of which were engineered from engrafted fully chimeric recipients. Acute GVHD did not arise after 
CAR-T infusion; one patient with stage 1 acute skin GVHD before study enrollment developed 
chronic GVHD requiring corticosteroid therapy 3 months after CAR-T infusion. Similarly, the group 
from Seattle Children’s Research Institute 11 used a defined ratio of 1:1 CD4: CD8 CD19 CAR-T cells 
in patients with B-ALL.  Among 27 of 45 patients who had previously undergone allo-HCT, only one 
developed grade 3 acute skin GVHD following CAR-T infusion. This patient had a prior history of 
GVHD and discontinued immunosuppression 1 year before CAR-T treatment.  
There have been four published studies
15, 19-21
 of donor-derived anti CD19 CAR-T therapy with three 
studies using a CD28 costimulatory domain and one with a 41BB co-stimulatory domain including 
one study where donor-derived multi-virus specific T-cells were transduced with a CD19-CAR28z 
construct to prevent and treat viral infection and relapse after allo-HCT.
21
 Smith et al. compiled the 
data for 49 patients from these four trials and reported that in patients who received donor-derived 
DLI, the total incidence of GVHD was 14% (n= 7), with an incidence of acute and chronic GVHD of 
8% (n=4) and 6% (n=3), respectively
22
. The GVHD incidence appeared to be lower when recipient-
derived (though largely likely of donor origin) rather than donor-derived CAR-T were used, 
suggesting that recipient-derived donor T cells were likely tolerized. It is important to note that 
tisagenlecleucel is an autologous product and the option to manufacture from the donor is not 
available. Taken together, the findings suggest that previous allo-HCT does not impact outcomes after 
recipient derived anti CD19 CAR-T therapy, making CAR-T therapy an excellent option for relapse 
after allo-HCT.  
For patients who have relapsed after allo-HCT and are evaluated for CAR-T therapy, it is suggested to 
stop any systemic drug used to prevent or treat grade 2-4 acute GVHD or extensive chronic GVHD at 
least 2 weeks prior to leukapheresis (Figure 2). The ELIANA trial allowed topical steroids for 
localized treatment of GVHD. It is important to note that if grade 2 or higher acute GVHD or severe 
chronic GVHD develop after leukapheresis, the patient should not undergo CAR-T infusion, and the 
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leukapheresis product or resulted manufactured CAR T-cells should not be used. Systemic therapy for 
GVHD after CAR-T infusion, being T cell directed, would terminate the therapeutic effect. 
 
6.  How is Cytokine Release Syndrome diagnosed and what are the treatment considerations?  
Key CRS manifestations include fever (92%), hypotension (67%), hypoxia (20%) and tachycardia 
(30%), but may also be associated with hepatic, renal, and cardiac dysfunction, and coagulopathy.
2
  
CRS begins with fever, and onset of severe CRS is most often indicated by unstable hypotension. 
Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following 
treatment with tisagenlecleucel in 54 (79%) of 68 pediatric and young adult patients with 
relapsed/refractory B-ALL. CRS severity was at least grade 3 (Penn grading system) in approximately 
half (49%) of all patients with a median time to onset of 3 days (range: 1-51 days); only in two 
patients did CRS begin after day 10. CRS resolution occurred at a median of 8 days (range: 1-36). 
Twenty-seven (50%) of the 54 patients with CRS were treated with tocilizumab; 7 (13%) received 
two doses, 3 (6%) received three doses, and 14 (26%) also received additional corticosteroids. Two 
deaths occurred within 30 days of tisagenlecleucel infusion, one due to CRS and progressive 
leukemia, and the other due to intracranial hemorrhage in the context of resolving CRS with 
abdominal compartment syndrome, coagulopathy, and renal failure.  
 
Risk factors for severe CRS in this patient population are high pre-infusion tumor burden (>50% 
marrow blasts), leukemia growing through lymphodepleting chemotherapy, high T cell dose, active 
infections, and/or other inflammatory processes. As a result, patients with rapidly accelerating 
extramedullary disease despite lymphodepleting chemotherapy, or patients with active infection, are 
likely to not be candidates for this therapy. 
 
In the ELIANA trial, the Penn grading scale was used to diagnose CRS. Currently, multiple CRS 
grading system have been used in various clinical trials including the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) system, Lee et al.
23
 and Neelapu et al.
24
 scales, all of which 
have advantages and disadvantages. Given the need for uniformity and replicability, ASBMT has 
developed a harmonized CRS grading scale for toxicity assessments, thus readers are directed to that 
paper for assessments and exact definitions of toxicity of CAR-T cells.  
 
Because of the risk of CRS and neurological toxicities, KYMRIAH (tisagenlecleucel) is available 
only through a restricted program under a REMS called the KYMRIAH REMS. Two doses of 
tocilizumab must be available on site for each patient prior to infusion of CAR-T therapy. Monitoring 
patients for signs or symptoms of CRS for at least 4 weeks after treatment with tisagenlecleucel is 
necessary. When patients are treated in the outpatient setting, patients must remain within 1-2 hours 
of the hospital and to seek immediate medical attention should signs or symptoms of CRS occur at 
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any time. At the first sign of CRS (fever), immediate hospitalization is imperative to allow prompt 
institution of treatment with supportive care, tocilizumab and/or corticosteroids (as indicated). When 
patients are admitted for fever, immediate management is focused in febrile neutropenia.  
 
7. How do we diagnose and manage neurotoxicity after CAR-T therapy?  
Neurotoxicity is an acknowledged challenge after CAR-T, however in contra-distinction to CRS, the 
exact pathogenesis and optimal management of CAR-T mediated neurologic toxicities remains to be 
better defined and studied in animal models
25, 26
. The onset of neurological toxicity is most commonly 
concurrent with or following resolution of CRS although it can also occur in the absence of CRS. The 
most common neurological toxicities observed with tisagenlecleucel include headache (37%), 
encephalopathy (34%), and delirium (21%)
2
. Neurological toxicities including severe or life-
threatening reactions occurred in 49 (72%) of 68 patients with relapsed/refractory B-ALL following 
treatment with tisagenlecleucel including at least grade 3 events in 21% of patients. Eighty-eight 
percent of these neurological toxicities occurred within 8 weeks following tisagenlecleucel infusion 
and were managed primarily with supportive care; no cerebral edema has been reported. Very few 
patients received steroids for neurological toxicities. Median time to the first event was 6 days from 
infusion (range: 1-359), and the median duration was 6 days with resolution occurring within 3 weeks 
for 79% of patients. The consensus neurotoxicity grading system does not include headache as part of 
the grading system, since headache is nearly universal in patients with CRS. 
When managing neurotoxicity, it is important to exclude alternative etiologies, especially infectious 
causes, stroke or hemorrhage. The extent of work-up (e.g. magnetic resonance imaging, 
electroencephalogram, cerebrospinal fluid analysis in selected patients) can be tailored to the severity 
and nature of symptoms. Imaging may also be useful to detect cerebral edema, which has been 
reported with other anti CD19 CAR T-cell products used for the treatment of B-ALL but has not been 
reported with tisagenlecleucel to date.
2, 8, 11, 27, 28
 Patients with a negative work-up may be treated 
expectantly. Levetiracetam or alternative anti-seizure prophylaxis for patients with a history of 
seizures or a history of prior neurotoxicity should be considered. In the ELIANA trial, 10 (13%) 
patients with CNS-2 disease (CSF containing blasts, but < 5 WBCs/microliter) received 
tisagenlecleucel. Neurotoxicity did not appear to be more severe in patients with CNS involvement 
than in those with bone marrow involvement only. Patients with frank CSF leukemia should not 
receive CAR-T cells until central nervous system (CNS) disease is improving or completely resolved.  
 
8. How should we monitor response after CAR-T therapy? 
Initial response assessment after CAR-T therapy for B-ALL should occur 3-4 weeks after CAR-T. 
Patients with B-ALL who do not respond within 4 weeks of CAR-T therapy are unlikely to respond, 
although resolving MRD-level disease has been seen in a small number of patients.  Response 
assessments after CAR-T therapy are similar to response assessments performed after traditional 
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chemotherapy for B-ALL and should include complete blood count with differential, bone marrow 
biopsy and aspirate, and a lumbar puncture (with or without a history of CNS disease). Assessment 
for MRD should be performed when available due to its prognostic importance. There are advantages 
and disadvantages of both Immunoglobulin next generation sequencing (NGS) and flow cytometry 
assays for detection of MRD. A flow cytometry assay for MRD is useful to identify surface markers 
(particularly CD19, but also CD22, and CD20) with therapeutic implications, while NGS based MRD 
may be more sensitive to detect lower levels of disease and has been strongly correlated with outcome 
after tisagenlecleucel
13
. When using flow cytometry assay to identify MRD, it is important to notify 
the laboratory performing MRD assessment that the patient received a CD19 targeted product and is 
at risk for a CD19-negative relapse which may impact design and interpretation of flow cytometry 
and possibly selection of future therapies.   
CAR-T can cross the blood brain barrier and have potential to target tumor cells within the CNS and 
provide ongoing leukemia surveillance.  For this reason, during CNS restaging after anti CD19 CAR-
T, administration of prophylactic intrathecal chemotherapy, due to its potential to kill CAR-T cells in 
this compartment, is not recommended. Of note, it is important to recognize that morphologically 
abnormal cells observed in CSF may be due to CAR-T cells (and not leukemia). In those situations, 
flow cytometry may be useful to differentiate CAR-T cells from residual lymphoblasts when there is a 
concern.  
Patients who achieve MRD-negative CR often have incomplete recovery of peripheral blood counts at 
the time of response assessment 
2, 7, 8, 13, 27
.  The reasons for this are multifactorial including heavily 
pretreated bone marrow, choice and intensity of bridging and/or lymphodepleting chemotherapy 
before CAR-T, and likely bone marrow suppression due to CAR-T expansion and resulting cytokine 
elevations. Incomplete count recovery at 4 weeks (even up to 3 months in some instances) should not 
be considered a negative prognostic sign. Most patients will slowly recover blood counts over 
subsequent weeks or months. 
Patients who have an initial response to therapy are at risk for relapse with either CD19-positive 
(often due to loss of CD19 CAR-T persistence) or CD19-negative (emergence of a resistant clone) 
disease.  Ongoing monitoring for relapse should be individualized. For a patient that does not receive 
further therapy after anti CD19 CAR-T, a reasonable monitoring approach is complete blood count 
with differential, and bone marrow biopsy and aspirate with assessment for MRD every 3 months for 
the 6-12 months after treatment. Obtaining peripheral blood B-cell counts monthly for the first 6 
months after treatment may allow detection of early loss of B-cell aplasia, which has been associated 
with an increased risk of relapse and may be used to stratify which patients are treated with 
subsequent allo-HCT and/or offered enrollment on clinical trials of reinfusion of CAR T-cells. Many 
trials use marrow surveillance out to a year, but at the very least, a marrow at 3 months is an excellent 
way to screen for hematogones, an indicator of early B cell recovery. This in turn may inform a 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
decision to reinfuse CAR-T cells or pursue allo-HCT.  The frequency of CSF evaluation can be 
individualized.  
 
9. How do we manage B cell aplasia and hypogammaglobulinemia after CD19-targeted CAR-T 
cell therapy? 
 
Specificity of CAR-T for target antigen is high; therefore, few off-target toxicities have been reported. 
Cytopenias following CAR-T cell therapy may be prolonged and have been associated with late 
infectious complications including fatal encephalitis and systemic mycosis. In the ELIANA trial, 53% 
of patients had grade 3 or 4 neutropenia that had not resolved by 28 days after infusion and 41% had 
grade 3 or 4 thrombocytopenia.  66% of these patients had resolution of neutropenia and 73% had 
resolution of thrombocytopenia to at least grade 2 by month 3.  Use of myeloid growth factors is not 
recommended within the first 3 weeks after treatment or until CRS has resolved but should be 
considered for patients with prolonged neutropenia. 
Conversely, on-target, but off-tumor toxicities are common.  For anti CD19 CAR-T therapy, B-cell 
aplasia is nearly universal following successful treatment and can be used as a pharmacodynamic 
marker of functional CAR-T cell persistence.
2, 8
.  Resultant hypogammaglobulinemia has been 
reported in 43% of children treated with tisagenlecleucel, but true rates of hypogammaglobulinemia 
are likely higher due to empiric immunoglobulin replacement in some patients before the 
development of laboratory-confirmed hypogammaglobulinemia.
2, 28
  Children have usually been 
treated with empiric immunoglobulin replacement similar to patients with X-linked 
agammaglobulinemia for the duration of functional CAR-T persistence, which appears to mitigate 
most acute infectious complications.  Whether this is required in adult patients who may have a 
greater repertoire of antibodies produced by pre-existing CD19-negative plasma cells is not yet clear.   
Prospective data on immunoglobulin replacement after CD19-targeted CAR-T cell therapy is 
currently unavailable, however, as severe hypogammaglobulinemia may increase risk for respiratory 
tract and other infections with encapsulated bacterial organisms (e.g. Streptococcus pneumoniae and 
Haemophilus influenzae type b), testing of serum IgG levels frequently after CD19-targeted CAR-T 
therapy, and administration of intravenous immunoglobulins to keep levels of IgG>400 mg/dL may 
be considered until long term data on the association of hypogammaglobinemia with infections is well 
established. Patients with prolonged (>6 months) B cell aplasia have been managed with 
subcutaneous immunoglobulin products, which can be administered at home and result in higher 
steady state IgG levels. Since prospective data on immunoglobulin replacement dosage is unavailable 
currently, institutional policies should be followed if replacement is undertaken. Long term follow-up 
will be required to understand the long-term effects of B-cell aplasia in both children and adults. 
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10.  What are the late effects of CAR-T therapy?  
Most patients participating in CAR-T trials have been followed for one or two years after treatment. 
Thus, the ability to assess the risk of long-term adverse events and late toxic effects of CAR-T, 
including tisagenlecleucel, is currently limited, although some potential late effects are theoretically 
predictable. To date, the main concerns regarding potential long-term sequelae of CAR-T include 
persistent cytopenias, prolonged B cell aplasia with acquired hypogammaglobulinemia, risks for 
infections, secondary malignancies, and new incidence or exacerbation of neurologic or autoimmune 
disorders 
29, 30
.   
While there is a theoretical risk for potentiation of alloreactive T-cells in patients who have undergone 
prior allo-HCT and still have donor T-cell engraftment, to date, development of GVHD directly as a 
result of CAR-T has not been reported despite >50% of patients having prior allo-HCT in clinical 
trials of tisagenlecleucel for pediatric leukemia.
2, 8, 11, 27, 28
  It is notable that these trials excluded 
patients with significant GVHD and required a washout period off immunosuppression prior to 
apheresis.  Attention should be paid to these criteria when patients are considered for commercial 
CAR-T cell therapy. 
 
Infections 
Patients treated with anti CD19 CAR-T for B-cell hematologic malignancies are at high risk of 
infection due to prior cytotoxic treatments, development of CRS, the risk for prolonged and B-cell 
aplasia with associated hypogammaglobulinemia. Thus, antimicrobial prophylaxis is recommended 
depending on institutional guidelines for CAR-T cells. (Table 2) Potential regimens include: 
levofloxacin for gram-negative bacteria prophylaxis while patients are neutropenic, fluconazole or 
micafungin for Candida species prophylaxis while patients are neutropenic, trimethoprim-
sulfamethoxazole (or pentamidine if allergic) for pneumocystis jiroveci prophylaxis for ≥3 months 
after CD19-targeted T cell therapy, and acyclovir for herpes simplex virus and varicella zoster virus 
prophylaxis for ≥3 months after CD19-targeted T cell therapy31, 32. 
 Approximately 20-40% of patients develop infections within the first month after CAR-T therapy 
despite antimicrobial prophylaxis
31, 32
. Bacterial and viral infections are the most common, although 
invasive fungal infections have also been described. Clinically significant reactivation of latent DNA 
viruses (e.g. cytomegalovirus, Epstein-Barr virus, BK polyomavirus) do not appear to be common, 
albeit prospective screening studies are lacking. 
The incidence and severity of late infections after CAR-T therapy are not well described. Limited data 
suggest a low incidence of late infections, most of which are mild and due to respiratory viruses 
31-33
. 
Careful monitoring for other infections is warranted as clinical use of CD19-directed CAR-T therapy 
expands to include more patients with chronic infections, such as hepatitis B, which may reactivate in 
this clinical setting. At this time there are data to regarding HBV reactivation after CD19-directed 
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CAR-T therapy, and there is no data to suggest HBV reactivation prophylaxis. At this time safety 
data for CAR-T therapy in human immunodeficiency virus (HIV) affected patients are not yet 
available, as this patient population has been excluded from CAR-T clinical trials. Of notice, some 
screening tests for HIV may lead to false positive results in case lentiviral vectors are used to produce 
CART cells.  
 
Vaccinations 
At this time there are no data to guide vaccination in this patient population. Studies of patients with 
B-cell depletion after rituximab have demonstrated the potential ability to mount responses to 
vaccines, particularly > 6 months after therapy and when conjugated vaccines are used, even in the 
absence of measurable peripheral blood B-cells 
34
. Limited evidence from patients after anti CD19 
targeted CAR-T therapy suggest that the preexisting levels of antibodies may not be affected given 
that antigen-specific IgG may be produced by long-lived plasma cells that do not express surface 
CD19 
35
.  However, the B cell aplasia in CAR-T patients can be absolute, and there is no IgA or IgM 
(especially in children), questioning the efficacy of vaccinations in these populations, thus might need 
to wait until there is evidence of B cell recovery before commencing vaccinations.  
While there is no data to guide vaccination in this patient population is available, guidelines from the 
Infectious Disease Society of America for immunocompromised or cancer patients and the US 
Advisory Committee on Immunization Practices may be considered in individuals with a complete 
response for ≥ 6 month 36, 37. However, many groups are waiting for resolution of B-cell aplasia before 
restarting vaccination. IVIg products supply antibody protection in patients with B-cell aplasia. Thus 
decision to start vaccinations while receiving IVIg should be prioritized based on institutional 
guidelines or on individual basis. Once vaccination decision has been made, priority should be given 
to inactivated influenza vaccines, the 13-valent Pneumococcal conjugate vaccine (Prevnar 13), and 
Haemophilus influenzae type b (Hib) conjugate vaccine. Serologic testing should ideally be obtained 
to evaluate the need for vaccination and to test for responses. Vaccination schedules similar to those 
given after HCT may be needed to elicit responses 
38
. Data from ongoing observational studies would 
be essential in order to generate future recommendations for vaccinations after CD19-targeted CAR-T 
cell therapy.   
 
Subsequent malignancies: 
Retroviral and lentiviral gene transfer systems are the most commonly used vectors in the genetic 
modification of T-cell therapies. Vectors derived from these families of viruses come with two 
potential risks: (i) the production of replication-competent viruses (RCV) and (ii) insertional 
mutagenesis, specifically oncogenic activation. Results of RCV testing from CAR-T trials 
demonstrate no risk to date 
39
. Similarly, a number of clinical trials with gamma-retroviral and 
lentiviral modified T-cells have not yielded evidence for insertional mutagenesis in T cells despite 
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long-term persistence of transduced cells. The safety profile in studies to date show no evidence of 
vector-induced immortalization, clonal expansion, or enrichment for integration sites near genes 
implicated in growth control or transformation 
40-42
. While the risk seems very low, clinical 
monitoring for secondary malignancies and long-term follow-up after CAR-T therapy should continue 
to be part of clinical trial protocols and is being requested as part of the long-term follow-up by FDA 
and European Medicines Agency (EMA). A post-marketing, prospective, multi-center, observational 
study to assess the long-term safety of tisagenlecleucel and the risk of secondary malignancies 
occurring after treatment with tisagenlecleucel, is required by the FDA. Per the FDA requirements the 
study should include at least 1000 pediatric and young adult patients with relapsed / refractory B-
ALL, and the enrolled patients should be followed for 15 years.
43
 
 
Neurologic disorders: 
Acute neurotoxicity after CAR-T therapy is well documented, with symptoms including confusion, 
delirium, expressive aphasia, obtundation, myoclonus, seizure, and cerebral edema 
24, 44
 as described 
earlier in this manuscript. The exact pathophysiology of CAR-T induced neurotoxicity is unclear, but 
two explanations have been suggested (i) passive diffusion of cytokines, such as IL-6 and IL-15, 
through the blood brain barrier, and (ii) trafficking of the CAR-T into the CNS 
24
. Disruption of the 
blood–brain barrier may also be a contributory factor 44. Although most cases of neurological toxicity 
seem reversible, data regarding long term neurological sequelae of CAR-T therapy are not available. 
Until data is available, patients who developed acute neurotoxicity after CAR-T infusions should be 
vigilantly monitored with history and complete neurologic exam. Furthermore, there should be a low 
threshold for performing neurocognitive testing if cognitive impairment is detected, noting that these 
patients will have received other chemotherapy and/or HCT as well. No data are currently available 
regarding late autoimmune disorders. 
 
Conclusions:  
Data regarding CAR-T late effects are still limited. Detection of these effects requires ongoing long-
term follow-up and enhanced clinical awareness by clinicians caring for patients after CAR-T therapy 
worldwide. A 15-year follow-up is requested as part of the marketing authorization of tisagelecleucel 
and axicabtagene ciloleucel, both by FDA and EMA. Continental registries such as CIBMTR or 
EBMT may become essential tools for this endeavor, helping to capture infrequent and delayed 
events, including the outcome of pregnancies in patients or partners. We hope that this paper will be 
helpful for the clinical management of issues revolving around CAR-T and allo-HCT in 
relapsed/refractory B-ALL patients. 
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Figure 1: Indications for referral to center performing CAR-T therapy for evaluation of 
relapsed/refractory ALL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4 Second or great bone marrow or extramedullary relapse
4 Refractory* disease (after initial diagnosis or first relapse)
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For potential Kymriah use in future or clinical trials
* Refractory is undefined in FDA label. ELIANA trial defined - Primary refractory, as not achieving 
complete remission (CR) after 2 cycles of a  standard chemotherapy regimen, or chemorefractory, 
defined as not achieving CR after 1 cycle of standard chemotherapy for relapsed leukemia. 
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Figure 2: Recommended timing to stop therapies prior to leukapheresis 
 
 
 
(Abbreviations: GVHD – Graft Versus Host Disease, CNS – Central Nervous System)  
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Table 1: Suggested treatment options for bridging 
chemotherapy or radiotherapy between leukapheresis and 
CAR-T therapy 
BRIDGING 
CHEMOTHERAPY 
CONSIDERATIONS 
TIME LINE TO STOP 
CHEMOTHERAPY/RADIOTHE
RAPY 
Systemic steroids, 
Hydrea, and Tyrosine 
kinase inhibitors 
STOP > 3 days prior to to 
tisagenlecleucel infusion 
Systemic 
Chemotherapy 
 vincristine 
 6mercaptopurine 
 6-thioguanine 
 methotrexate 
<25 mg/m2  
 cytosine 
arabinoside <100 
mg/m2/day 
 asparaginase 
(nonpegylated)  
CNS disease 
prophylaxis 
STOP >1 week prior to 
tisagenlecleucel infusion  
(No drug should be administered 
concomitantly or following 
lymphodepleting chemotherapy)  
Salvage 
chemotherapy e.g.,  
 cytosine 
arabinoside >100 
mg/m2 , 
anthracyclines,  
 cyclophosphamid
e, methotrexate 
≥25 mg/m2 
Radiation therapy at 
non-CNS site 
STOP > 2 weeks prior 
tisagenlecleucel infusion  
Pegylated asparginase  STOP > 4 weeks prior to 
tisagenlecleucel infusion  
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Anti-T Cell antibodies 
CNS directed radiation 
STOP > 8 weeks prior to 
tisagenlecleucel infusion  
 
Avoid therapies (in particular – clofarabine) which are likely to 
significantly impart lymphocyte number and/or function 
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Table 2: Infection prophylaxis for patients 
undergoing anti CD-19 CAR-T therapy. 
Infection Prophylaxis and duration * 
Gram-negative bacteria 
Levofloxacin (while patients 
are neutropenic) 
Candida species Fluconazole or micafungin 
Pneumocystis jiroveci 
Trimethoprim-
sulfamethaxazole (or 
pentamidine if allergic) for ≥ 
3 months after CD19 targeted 
T cell therapy 
Herpes simplex virus and 
varicella zoster virus 
Acyclovir or valacyclovir for 
≥ 3 months after CD19 
targeted T cell therapy 
* For patients with allergies to particular medications, 
substitute with appropriate alternatives per institutional 
guidelines.  
 
 
